Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Interferons and ribavirin

Bocher WO, Schuchmann M, Link R, Hillenbrand H, Rahman F, Sprinzl M, Mudter J, Lohr HF, Galle PR (2006) Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver Int 26 319-325... [Pg.231]

Adherence to therapy is another important factor in increasing and maintaining SVR. Patients who were adherent with interferon and ribavirin therapy (taking more than 80% of doses for more than 80% of the treatment duration) had an SVR of 52% whereas those who were not compliant had an SVR of 44% 42... [Pg.356]

At present, pegylated interferon plus ribavirin is the regimen of choice for the treatment of hepatitis C.41 Interferon, pegylated interferon, and ribavirin have significant adverse effects, as discussed below. [Pg.356]

The type and incidence of adverse effects associated with unmodified interferon and pegylated interferon are comparable. Approximately 10% to 30% of patients receiving interferon and/or ribavirin require a dosage reduction or treatment discontinuation to minimize side effects. Patients should be screened for uncommon adverse effects and laboratory abnormalities prior to starting interferon and ribavirin because treatment may exacerbate or worsen some medical conditions. [Pg.356]

About 10% to 25% of patients treated with interferon and ribavirin require dosage reductions when hemoglobin levels decrease or they develop intolerable symptoms such as shortness of breath or severe fatigue. If warranted, erythropoietin may be used as adjunctive therapy for ribavirin-induced hemolytic anemia.45... [Pg.357]

Adverse effects of interferon, pegylated interferon, and ribavirin therapy... [Pg.358]

Vidigal, P. G., Germer, J. J., and Zein, N. N., Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-betal genes in chronic hepatitis C patients treated with interferon and ribavirin, J. Hepatol., 36, 271, 2002. [Pg.93]

Hypersensitivity reactions Severe acute hypersensitivity reactions (eg, urticaria, angioedema, bronchoconstriction, anaphylaxis) have been rarely observed during alpha interferon and ribavirin therapy. [Pg.1990]

Pancreatitis Pancreatitis, sometimes fatal, has occurred during alpha interferon and ribavirin treatment. [Pg.1990]

D. Interferons and ribavirin are both likely to cause anemia the combination of these two agents increases this possibility. Interferons do not stimulate lymphocyte proliferation. [Pg.582]

McHutchison JG, Fried MW Current therapy for hepatitis C Pegylated interferon and ribavirin. Clin Liver Dis 2003 7 149. [PMID 12691464]... [Pg.1209]

Disis ML, Feld JJ Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005 436 967. [Pg.1209]

Sauleda, S., Juarez, A., Esteban, J. I., Altisent, C., Ruiz, I., Puig, L., Esteban, R., Guardia, J. 2001. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology, 34(5), 1035-1040. [Pg.351]

Chandhari, S., Park, J., Anand, B.S., Pimstone, N.R., Dieterich, D.T., Batash, S., Binl, E.J. Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Dig. Dis. Sci. 2004 49 1000-1006... [Pg.713]

Gitlin, N. Manifestation of sarcoidosis during interferon and ribavirin therapy for chronic hepatitis C a report of two cases. Eur. J. Gastroenterol. Hepatol. 2002 14 883-885... [Pg.713]

Thnlnvath, P.J., Pande, H., Maygers, J. Combination therapy with interferon-alpha (2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin. Dig. Dis. Sci. 2003 48 594- 597... [Pg.714]

Mazzaferro, V., Tagger, A., Schiaro, M., Regalia, E., Pulvirenti, A., Ribero, M.L., Coppa, J., Romito, R., Burgoa, L., Zncchini, N., Urba-nek, T., Bonino, F. Prevention of recurrent hepatitis C after hver transplantation with early interferon and ribavirin treatment. Transplant. Proc. 2001 33 1355-1357... [Pg.890]

Karim A, Ahmed S, Khan A, Steinberg H, Mattana J. Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection. Am J Med Sci 2001 322(4) 233-5. [Pg.1819]

Kumar AS, Russo MW, Esposito S, Borezuk A, Jacobson I, Brown M, Brown RS. Severe pulmonary toxicity of interferon and ribavirin therapy in chronic hepatitis C. Am J Gastroenterol 2001 96(Suppl) 127. [Pg.1819]

Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002 97(9) 2432-40. [Pg.1820]

The adverse effects and other safety aspects of interferon and ribavirin in the treatment of hepatitis C infection have been reviewed (10). [Pg.3037]

Suoglu D OD, Elkabes B, Sokucu S, Saner G. Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C J Pediatr Gastroenterol Nutr 2002 34(2) 199-206. [Pg.3039]

Tan AC, Brouwer JT, Glue P, vau Leuseu R, Kauffmann RH, Schalm SW, de Vries RA, Vroom B. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C results of a pilot study. Nephrol Dial Transplant 2001 16(1) 193-5. [Pg.3039]

Gordon A, Menahem S, Mitchell J, Jenkins P, Dowling J, Roberts SK Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating igA nephropathy, Nephrol Dial Transplant 2004,19 2155... [Pg.696]

What are common side effects of interferon and ribavirin ... [Pg.139]

Interferon and ribavirin are indicated for the treatment of chronic hepatitis C with compensated liver disease. Compensated liver disease typically is defined as no history of hepatic encephalopathy, variceal hemorrhage, ascites, or other signs of decompensation. In addition, laboratory values should be near normal (bilirubin < 2 mg/dU stable [near normal] albumin, PT < 3 second prolongation, WBC > BOOO/imm, platelets > 70,000/mm3,... [Pg.139]

The combination of interferon and ribavirin has a significant benefit on sustained virologic response (the absence of detectable HCV RNA more than 6 months after treatment), biochemical response (normalization of transaminases), and liver histology in patients with hepatitis C compared with interferon by itself. Ribavirin is ineffective by itself and should not be used as monotherapy. [Pg.139]

Case Conclusion The patient is a candidate for interferon and ribavirin as part of the management of his chronic HCV infection to prevent progression of his disease. [Pg.140]

See other pages where Interferons and ribavirin is mentioned: [Pg.77]    [Pg.235]    [Pg.240]    [Pg.330]    [Pg.345]    [Pg.356]    [Pg.356]    [Pg.357]    [Pg.1991]    [Pg.182]    [Pg.351]    [Pg.152]    [Pg.714]    [Pg.714]    [Pg.3037]    [Pg.502]    [Pg.1562]    [Pg.1577]    [Pg.1577]    [Pg.1802]   
See also in sourсe #XX -- [ Pg.257 ]



SEARCH



Interferon + ribavirin

© 2024 chempedia.info